Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study
Metformin decreases bone turnover markers in polycystic ovary syndrome: a post hoc study
复制标题
二甲双胍可降低多囊卵巢综合征患者的骨转换标志物水平：一项事后研究
DOI：
10.1016/j.fertnstert.2019.04.013
复制
发表时间：
2019-08-01
影响因子：
6.7
通讯作者：
Tapanainen, Juha S.
中科院分区：
文献类型：
--
作者：
Lingaiah, Shilpa;Morin-Papunen, Laure;Tapanainen, Juha S.
目的：研究二甲双胍治疗对多囊卵巢综合征（PCOS）妇女骨转换的影响，通过测定血清骨转换标志物的浓度。设计：先前进行的前瞻性多中心、安慰剂对照、随机研究的事后研究。设置：大学诊所。患者：研究队列包括74名非肥胖女性（体重指数< 27 kg/m2）和44名肥胖妇女（体重指数>= 27 kg/m2）诊断为PCOS，平均年龄27.6 ± 4.0（SD）岁。干预：随机接受二甲双胍或安慰剂治疗3个月。主要结果测量：在基线和二甲双胍/安慰剂治疗后，骨形成标志物I型前胶原氨基末端前肽（PINP）和骨吸收标志物I型胶原羧基末端交联端肽（CTX）的血清水平。在整个研究人群中，二甲双胍组和安慰剂组基线时的PINP和CTX血清水平相似。与非肥胖女性相比，肥胖女性的PINP和CTX基线水平较低。二甲双胍治疗3个月后，整个研究人群以及非肥胖和肥胖女性的PINP和CTX水平均显著降低，而安慰剂组未观察到显著变化。与安慰剂相比，二甲双胍治疗与骨转换减少有关，这是由骨形成和骨吸收标志物的减少所表明的，导致绝经前多囊卵巢综合征妇女骨重建较慢。((C)2019年由美国生殖医学学会（American Society for Reproductive Medicine）
Objective: To study the effects of metformin treatment on bone turnover in women with polycystic ovary syndrome (PCOS), as measured by serum concentrations of bone turnover markers.Design: Post hoc study of a previously conducted prospective multicenter, placebo-controlled, randomized study.Setting: University clinic.Patient(s): The study cohort consisted of 74 non-obese women (body mass index < 27 kg/m(2)) and 44 obese women (body mass index >= 27 kg/m(2)) diagnosed with PCOS, with a mean age of 27.6 +/- 4.0 (SD) years.Intervention(s): Randomization to receive metformin or placebo for 3 months.Main Outcome Measure(s): Serum levels of bone formation marker procollagen type I amino-terminal propeptide (PINP) and bone resorption marker carboxy-terminal cross-linking telopeptide of type I collagen (CTX) at baseline and after metformin/placebo treatment.Result(s): Serum levels of PINP and CTX were similar between the metformin and placebo groups at baseline in the whole study population. Obese women, when compared with non-obese, had lower baseline levels of PINP and CTX. Levels of PINP and CTX were significantly reduced in the whole study population, as well as in both non-obese and obese women after 3 months of metformin treatment, whereas no significant changes were observed in the placebo group.Conclusion(s): Metformin treatment, when compared with placebo, was associated with reduced bone turnover, as suggested by reductions in markers of bone formation and resorption, leading to slower bone remodeling in premenopausal women with PCOS. ((C) 2019 by American Society for Reproductive Medicine.)